Global renal disease treatment devices market is expected to grow at a rapid pace due to rising incidences of chronic kidney disorders (CKD) and end-stage renal disease (ESRD). Rising patient base of hypertension and lifestyle associated diseases are the major reasons behind increasing kidney-related diseases which are expected to drive the demand for treatment devices during the forecast period. Increasing the geriatric population base is also one of the key drivers for this market as aging is the common factor responsible for increasing incidences of renal diseases. As per the WHO report of 2011, more than 190 million people were suffering from chronic kidney disorders and 220 million males were suffered from diseases of prostate glands worldwide is anticipated to grow progressively over the decade. This rising incidence rate of renal diseases has shifted doctor’s preferences towards the use of advanced renal disease treatment devices enabling reduced treatment and recovery time. Other market drivers such as improvising healthcare infrastructure, the introduction of novel therapies in renal disease treatment devices especially in developed countries are expected to boost the market over the forecast period. The development of safe and effective novel therapies for renal disease treatment is contributing to the growth of this market.
Technological advancements such as point of care drug delivery systems and a growing emphasis on maintaining the quality of life are the factors promoting the growth of this market. Additionally, increasing R&D expenditures, supportive government policies, and increasing usage of personalized medicines are further expected to fuel the market growth of renal disease treatment devices market over the forecast period. The renal disease treatment devices market is segmented on the basis of treatment and devices. Treatment procedures for renal diseases include hemodialysis dialyzers and kidney transplants. Hemodialysis dialyzer accounted for one of the largest market shares as of 2014, owing to its extensive usage by ESRD patients. On the basis of types of devices market segmented into devices for urinary stone treatment, dialysis, pelvic organ prolapse treatment, endoscopy, benign prostatic hyperplasia treatment devices, prostatic stents, lithotripsy, sacral neuromodulation, urethral inserts & pessaries, urethral stents, vaginal meshes & slings, peritoneal dialysis, catheter ablation, and urinary stone treatment. The dialysis segment held the largest market share due to rising incidences of CKD. A peritoneal dialysis catheter is less costly than other dialysis treatments and expected to use on large scale by patients.
On the basis of geography, the market is segmented into North America, Asia Pacific, Latin America, Middle East Asia, and Europe. North America was the largest revenue-generating market in 2014 owing to the presence of sophisticated healthcare facilities and supportive government policies. In the U.S. new prospective payment system was initiated on January 1, 2011, named ESRD reimbursement system. This system combines the payments for dialysis, drugs, and lab tests into one single payment to control the cost of dialysis treatments which expected to drive the market at a rapid pace. Increasing adoption of technologically advanced devices especially in the hospitals, fueling the growth of the U.S. market during the forecast period. The European market, owing to the rising geriatric population database and prevalence of chronic diseases is expected to drive the demand for renal disease treatment devices. Increasing healthcare expenditure, untapped opportunities, and government funding for R&D in Asia pacific region are expected to drive the regional renal disease treatment devices market during the forecast period. Emerging economies such as India and China are major contributors to the growth of the Asia Pacific market.
Key market players studied are Fresenius Medical Care, Dornier Medtech, Baxter International, C.R. Bard, Asahi Kasei Corp., Jolla Pharmaceutical Company, Terumo Corporation, and B Braun Group. Companies are adopting competitive strategies such as new product development, collaborations, merger & acquisitions, and partnerships. Baxter international acquired Gambro (Sweden) in September 2013, in an attempt to extend its dialysis product portfolio and market penetration in the European market. Similarly, ongoing research by La Jolla Pharmaceutical Company shows positive results for phase II clinical trials on novel drugs, such as GSC-100 drug molecules in CKD are also expected to drive the growth of renal disease treatment devices market.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.